Related references
Note: Only part of the references are listed.Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure
Kevin S. Shah et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2022)
Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients
Atsunori Kashiwagi et al.
JOURNAL OF DIABETES INVESTIGATION (2021)
Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes
Vincent C. Woo
CANADIAN JOURNAL OF DIABETES (2020)
SGLT2 inhibitors - a potential treatment for Alport syndrome
Holly Mabillard et al.
CLINICAL SCIENCE (2020)
SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
Milton Packer
DIABETES CARE (2020)
Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance
T. Nojima et al.
DIABETIC MEDICINE (2020)
Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease
Kazuomi Kario et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2020)
SGLT2i: beyond the glucose-lowering effect
Lihua Ni et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials
Daisuke Yabe et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
Andre J. Scheen
CURRENT CARDIOLOGY REPORTS (2019)
Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
Claire C. J. Dekkers et al.
DIABETES OBESITY & METABOLISM (2019)
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
Pouya Saeedi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in East Asians with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Lidan Yang et al.
DIABETES THERAPY (2019)
Empagliflozin in type I diabetes
Chantal Mathieu et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2019)
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study
Anna Norhammar et al.
DIABETES OBESITY & METABOLISM (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice
A. Ram Hong et al.
DIABETES & METABOLISM JOURNAL (2019)
SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
Ven G. Lim et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Piero Baglioni
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis
Xiaoling Cai et al.
OBESITY (2018)
The effect of dapagliflozin treatment on epicardial adipose tissue volume
Takao Sato et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study
Julio Nunez et al.
CLINICAL CARDIOLOGY (2018)
Type 2 Diabetes in Youth: New Lessons from the SEARCH Study
Elizabeth T. Jensen et al.
CURRENT DIABETES REPORTS (2018)
Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial
Ryuzo Kawamori et al.
DIABETES OBESITY & METABOLISM (2018)
Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
Kyung-Ah Han et al.
DIABETES OBESITY & METABOLISM (2018)
Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics
Salvatore Carbone et al.
DIABETES OBESITY & METABOLISM (2018)
Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: A patient-level pooled analysis of 16 randomised controlled trials
Juliana C. N. Chan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Empagliflozin: A Review in Type 2 Diabetes
James E. Frampton
DRUGS (2018)
Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
Abdullah Kaplan et al.
HEART FAILURE REVIEWS (2018)
SGLT-2 Inhibitors and Cardiovascular Risk An Analysis of CVD-REAL
Matthew A. Cavender et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels
Hongliang Li et al.
LIFE SCIENCES (2018)
Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial
Wenying Yang et al.
JOURNAL OF DIABETES (2018)
Differential effect of body mass index on the incidence of diabetes and diabetic retinopathy in two Asian populations
Joel Chee Yee Chan et al.
NUTRITION & DIABETES (2018)
Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
Eugene Han et al.
DIABETES THERAPY (2018)
Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
Eugene Han et al.
DIABETES THERAPY (2018)
Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study
Takeshi Osonoi et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2018)
The effectiveness of dapagliflozin for sleep-disordered breathing among Japanese patients with obesity and type 2 diabetes mellitus
Shinya Furukawa et al.
ENDOCRINE JOURNAL (2018)
SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic β-cell death in genetically obese mice
Michael J. Jurczak et al.
ISLETS (2018)
A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2 inhibitor empagliflozin
Chung-Huei Huang et al.
ANNALS OF SAUDI MEDICINE (2018)
Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naive Subjects with Type 2 Diabetes
Eiji Kutoh et al.
DRUGS IN R&D (2018)
Prevalence and risk factors of gestational diabetes mellitus in Asia: a systematic review and meta-analysis
Kai Wei Lee et al.
BMC PREGNANCY AND CHILDBIRTH (2018)
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
A. K. Pancholia
INDIAN HEART JOURNAL (2018)
Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
Source of Chronic Inflammation in Aging
Fumihiro Sanada et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2018)
Diabetes in China: Epidemiology and Genetic Risk Factors and Their Clinical Utility in Personalized Medication
Cheng Hu et al.
DIABETES (2018)
Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
Kazuyuki Tobe et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
Tsung-Ming Lee et al.
FREE RADICAL BIOLOGY AND MEDICINE (2017)
Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China
Fiona Bragg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Islet inflammation in type 2 diabetes and physiology
Kosei Eguchi et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype
Lee Ling Lim et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2017)
Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes Systematic review and meta-analysis of randomized controlled trials
Yingying Yang et al.
MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Extracellular Fluid/Intracellular Fluid Volume Ratio as a Novel Risk Indicator for All-Cause Mortality and Cardiovascular Disease in Hemodialysis Patients
Eun-Jung Kim et al.
PLOS ONE (2017)
Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management
Arun Chaudhury et al.
FRONTIERS IN ENDOCRINOLOGY (2017)
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Proposal of a Novel Mechanism of Action
Milton Packer et al.
JAMA CARDIOLOGY (2017)
Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus
Nagashekhara Molugulu et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Characteristics of the pathophysiology of type 2 diabetes in Asians
Young Min Cho
ANNALS OF LAPAROSCOPIC AND ENDOSCOPIC SURGERY (2017)
Metabolic and inflammatory pathways on the pathogenesis of type 2 diabetes
Andressa Coope et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial
Chieh-Hsiang Lu et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
Christian Sonesson et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Diabetes in Asia and the Pacific: Implications for the Global Epidemic
Arun Nanditha et al.
DIABETES CARE (2016)
Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials
Kun-Ho Yoon et al.
DIABETES OBESITY & METABOLISM (2016)
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
Nelson B. Watts et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period
Eiichi Araki et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
Daisuke Yabe et al.
CURRENT DIABETES REPORTS (2015)
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Silvio E. Inzucchi et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
C. David Sjostrom et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY - CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN-2015
Yehuda Handelsman et al.
ENDOCRINE PRACTICE (2015)
Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
Aurora Merovci et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
Caroline Bonner et al.
NATURE MEDICINE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Empagliflozin in the treatment of type 2 diabetes: evidence to date
Jay H. Shubrook et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Bowen Lin et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States
Ronald C. W. Ma et al.
YEAR IN DIABETES AND OBESITY (2013)
Globalization of Diabetes The role of diet, lifestyle, and genes
Frank B. Hu
DIABETES CARE (2011)
Lipid homeostasis, lipotoxicity and the metabolic syndrome
Roger H. Unger et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2010)
Diabetes in Asia Epidemiology, Risk Factors, and Pathophysiology
Juliana C. N. Chan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians
Maggie C. Y. Ng et al.
DIABETES (2008)
Association study of the genetic Polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene and type 2 diabetes in the chinese population
Yi-Cheng Chang et al.
DIABETES (2007)
Epidemic obesity and type 2 diabetes in Asia
Kun-Ho Yoon et al.
LANCET (2006)
Share Paper
